Acumen Pharmaceuticals, Inc.

01/26/2026

Having strong company values is vital to building a positive work culture and driving Acumen's mission forward. We want to share our values with the world in the hope that they may inspire others to join us in making a meaningful impact.

At Acumen, our top priority is people. We believe that people are the heart and soul of our company, and we are committed to making a difference in the lives of those impacted by Alzheimer's disease.

By putting people first, we ensure that our research and development efforts are geared towards creating targeted treatments that improve the quality of life for patients as well as their families and caregivers.

01/20/2026

We’re pleased to share a new Clinical Leader feature highlighting how Acumen is using a “study within a study” approach to better understand what works in Alzheimer’s trial recruitment.

Our CMO, Eric Siemers MD, and Associate Director of Communications Robyn Moxon sat down with Abby Proch to discuss how taking a closer look at our own strategies can help improve efficiency, reduce burden, and inform future trial design across the field.

Read the full conversation here: https://www.clinicalleader.com/doc/study-within-a-study-reveals-best-recruitment-strategies-for-alzheimer-s-trials-0001

In this Q&A, Acumen Pharmaceuticals shares findings from its Alzheimers recruitment study, highlighting what efforts proved the most fruitful.

01/13/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

January's 'Ask Acumen' featured team member is Elizabeth Johnson, PhD, Senior Scientist, Discovery.

🔗Click the link below to get a behind-the-scenes look at Elizabeth's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

12/31/2025

Happy New Year from the Acumen Team - wishing you a healthy and hopeful 2026!

12/22/2025

This season, we're grateful for the moments of connection that move us forward, and for the patients, families, and partners who inspire our work every day.

Wishing you peace and joy during the holidays, and a hopeful start to the year ahead.

12/12/2025

Last week in San Diego, the Acumen team attended the CTAD Conference where we presented posters detailing a nonclinical Enhanced Brain Delivery (EBD™) study focusing on fusing transferrin receptor binders to sabirnetug to facilitate its transport through the blood-brain barrier as well as recruitment strategies for our Phase 2 ALTITUDE-AD study of sabirnetug.

To see our posters visit: https://acumenpharm.com/publications/

12/10/2025

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

December’s 'Ask Acumen' featured team member is Paul Shughrue, PhD, Research and Portfolio Lead.

🔗Click the link below to get a behind-the-scenes look at Paul’s journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

12/05/2025

All good things must come to an end, and while the Acumen team is sad to leave hashtag , it’s been a wonderful week of sharing knowledge and innovation in the ’s field. We’ll see you all next year!

12/04/2025

Today Elizabeth Johnson, PhD is presenting findings from a nonclinical study on Enhanced Brain Delivery (EBD™) focusing on fusing transferrin receptor binders to sabirnetug to facilitate its transport through the blood-brain barrier at CTAD Conference in San Diego.

Learn more about the presentation here: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-highlights-enhanced-brain-deliverytm

12/03/2025

It’s day 3 of and it has been a great conference so far - filled with insightful conversations and great connections!

We look forward to presenting findings from a nonclinical study of Enhanced Brain Delivery (EBD™) constructs of sabirnetug tomorrow, check it out at Poster #381 in San Diego and online.

12/02/2025

Today at CTAD Conference in San Diego, Robyn Moxon presented Acumen’s recruitment strategies for the Phase 2 ALTITUDE-AD study of sabirnetug. A special thank-you to Dr. Trinh for his thoughtful collaboration on this presentation and for helping elevate an important discussion around recruitment and representation in Alzheimer’s research.

12/02/2025

We’re pleased to share additional insights from our research programs at CTAD Conference 2025!

Visit our posters to learn more about:
➡P381 Enhanced brain delivery (EBD™) findings from a nonclinical study of EBD constructs of sabirnetug

➡P019 Recruitment learnings from the Phase 2 ALTITUDE-AD trial

🔗 Check out our posters at and read our press release for more details: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-highlights-enhanced-brain-deliverytm